

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Chaoju Eye Care Holdings Limited

朝聚眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2219)

VOLUNTARY ANNOUNCEMENT

ACQUISITION OF EQUITY INTERESTS IN THE BEIJING HOSPITAL

This announcement is made by Chaoju Eye Care Holdings Limited (the “**Company**”) on a voluntary basis to keep its shareholders and potential investors informed of the latest business development of the Company and its subsidiaries (the “**Group**”).

Acquisition of the Beijing Hospital

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on December 25, 2023, Xiamen Chaoju Letong Holdings Co., Ltd.* (廈門朝聚樂通控股有限公司) (“**Xiamen Chaoju Letong**”) and Xiamen Juwang Minghui Investment Partnership (Limited Partnership)* (廈門聚望明暉投資合夥企業(有限合夥)) (“**Xiamen Juwang**”), both of which are indirect wholly-owned subsidiaries of the Company, have completed the acquisition of 97% equity interests in Beijing Mingyue Ophthalmic Clinic Co., Ltd.* (北京明玥眼科診所有限公司) (the “**Beijing Hospital**”) at the consideration of RMB36.86 million (the “**Acquisition**”). Pursuant to the Acquisition, (i) Xiamen Chaoju Letong acquired 51% equity interests in the Beijing Hospital from Yu Mengyuan (于夢圓), a third party independent of the Company; and (ii) Xiamen Juwang acquired 10.29% equity interests in the Beijing Hospital from Yu Mengyuan and 35.71% equity interests in the Beijing Hospital from Taihua Dongyi (Beijing) Technology Development Co., Ltd.* (泰華東億(北京)科技發展有限公司), a third party independent of the Company. The remaining 3% equity interests in the Beijing Hospital is held by an individual, a third party independent of the Company. Upon completion of the Acquisition, the results of the Beijing Hospital will be consolidated into the financial statements of the Group.

Reasons for and benefits of the Acquisition

The Beijing Hospital, which is located in Beijing, presents a strategic benefit to the Group as it will be the integration platform for its resources in the northern region of China. The Group will be able to create synergies with the clustered operations of its various hospitals in the regions of Eastern Mongolia, Western Mongolia, Hebei, Shanxi and Ningxia, as they will collaborate and expand the Group's coverage, which will be significant to its future development in the core North China region and other northern regions.

In light of the above, the Directors are of the view that the terms of the Acquisition are fair and reasonable, and are on normal commercial terms and that the Acquisition is in the interest of the Company and its shareholders as a whole.

Listing Rules Implication

As none of the applicable percentage ratios (as defined in Rule 14.07 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) exceeds 5%, the Acquisition does not constitute any notifiable transaction of the Company under Chapter 14 of the Listing Rules.

By order of the Board
Chaoju Eye Care Holdings Limited
ZHANG Bozhou
Chairman

Hong Kong, January 2, 2024

As of the date of this announcement, the Board of Directors of the Company comprises Mr. ZHANG Bozhou as the chairman and executive Director; Ms. ZHANG Xiaoli, Mr. ZHANG Junfeng and Mr. ZHANG Guangdi as executive Directors; Mr. Richard Chen MAO, Mr. LI Zhen and Ms. ZHANG Li as non-executive Directors; and Mr. HE Mingguang, Ms. GUO Hongyan, Mr. LI Jianbin and Mr. BAO Shan as independent non-executive Directors.

** The English translation of the Chinese names denoted in this announcement is for illustration purposes only. Should there be any inconsistencies, the Chinese name shall prevail.*